Fujifilm cellular dynamics and sana biotechnology announce license agreement for the development of ipsc-derived cell therapies

Madison, wis. and seattle, march 17, 2021 (globe newswire) -- fujifilm cellular dynamics, inc., a leading global developer and manufacturer of human induced pluripotent stem cells (ipsc) technologies, and sana biotechnology, inc. (nasdaq: sana), a company focused on creating and delivering engineered cells as medicines, announced today that sana has been granted a non-exclusive right to use fujifilm cellular dynamics' ipsc platform for the development of commercial cell therapies. as a treatment modality, cell therapies have the potential to augment, repair, or replace human biology, including organs, tissues and cells.
SANA Ratings Summary
SANA Quant Ranking